tern-101
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04328077)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bile acid receptor FXRAGONIST
Bile acid receptor FXR agonist
- Bile acid receptor FXRINHIBITOR
NR1H4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(C(=O)O)c2ccc(N3CCC(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)CC3)cc21- Mol. weight
- 540.45 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3746388 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05415722 | Phase 2 | Jul 7, 2022 | Terns, Inc. |
| NCT04328077 | Phase 2 | Apr 30, 2020 | Terns, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Terns, Inc. | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1